Novartis Secures Landmark European Approval for New Oral Skin Therapy
Basel, Monday, 27 April 2026.
Novartis secured European approval for Rhapsido, the first oral targeted therapy for chronic hives. Requiring no liver monitoring, this breakthrough safely unlocks a highly lucrative market for investors.
A New Paradigm in Immunology
On April 27, 2026, the European Commission (EC) officially approved Rhapsido (remibrutinib) for adult patients suffering from chronic spontaneous urticaria (CSU) who have shown an inadequate response to H1-antihistamine treatments [1]. This regulatory decision marks Rhapsido as the first oral targeted therapy authorized for CSU, designed to be taken as a twice-daily pill without the need for routine laboratory monitoring [1]. The approval is heavily anchored by the results of the Phase III REMIX-1 and REMIX-2 clinical trials, which involved 925 patients and demonstrated the drug’s clear superiority over a placebo in reducing itch, hives, and overall urticaria activity by Week 12 of treatment [1].
Strategic Market Positioning and Financial Health
Beyond CSU, Novartis is aggressively expanding the application of its targeted oral BTK pathway approach across multiple immune-mediated conditions [1]. Active clinical trials are currently investigating remibrutinib’s efficacy in treating severe hidradenitis suppurativa (NCT03827798) and peanut allergies (NCT05432388) [5]. Furthermore, the ongoing REMODEL-1 and REMODEL-2 trials are evaluating the drug against teriflunomide for relapsing multiple sclerosis (RMS) [5]. Patrick Horber, M.D., President International at Novartis, emphasized that these parallel developments highlight the broad therapeutic potential of the company’s immunology pipeline [1].
Competitive Landscape and Future Outlook
Novartis operates in a fiercely competitive global pharmaceutical landscape, frequently contending with industry peers such as Pfizer, Merck, Johnson & Johnson, and Sanofi [4][6]. Sanofi, for instance, recently secured its own positive CHMP opinion on April 24, 2026, for its multiple sclerosis therapy Cenrifki (tolebrutinib) in the European Union [4]. However, Rhapsido’s unique profile—specifically its lack of required lab monitoring—provides Novartis with a distinct competitive advantage in the dermatology sector [1]. While the United States currently accounts for approximately one-third of Novartis’s total revenue [3], securing the European market for a first-in-class CSU treatment provides a critical diversification of income streams [GPT].